Chimeric HLA-A*02:01 (mα3) &mB2M&MAGE-A2 (KMVELVHFL) Monomer Protein 2057

Additional Information:
accession A0A140T913(Human HLA-A*02:01 1&2)&P01897(Mouse HLd 3)&&P01887(Mouse B2M)&KMVELVHFL|express systemHEK293|product tagC-His|purity> 95% as determined by Tris-Bis PAGE;> 95% as determined by HPLC|backgroundMelanoma antigen gene (MAGE)-A2 (MAGEA2) is a member of the MAGE-A family proteins widely studied for cancer vaccine development and identification of tumor markers. MAGEA2 plays an oncogenic role in glioma progression, and they provide insight into MAGEA2 application as a novel predictor of clinical outcomes and a potential glioma biomarker.|molecular weightThe protein has a predicted MW of 48.00 kDa. Due to glycosylation, the protein migrates to 50-65 kDa based on Tris-Bis PAGE result.|available size100 g, 500 g|endotoxinLess than 1EU per g by the LAL method.|Chimeric HLA-A*02:01 (m3) &mB2M&MAGE-A2 (KMVELVHFL) Monomer Protein 2057proteinSize and concentration100, 500g and liquidFormLiquidStorage InstructionsValid for 12 months from date of receipt when stored at -80C. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.Storage bufferShipped with dry ice.Purity> 95% as determined by Tris-Bis PAGEtarget relevanceMelanoma antigen gene (MAGE)-A2 (MAGEA2) is a member of the MAGE-A family proteins widely studied for cancer vaccine development and identification of tumor markers. MAGEA2 plays an oncogenic role in glioma progression, and they provide insight into MAGEA2 application as a novel predictor of clinical outcomes and a potential glioma biomarker.Protein namesMajor histocompatibility complex, class I, AGene namesHLA-A,HLA-AProtein familyMHC class I familyMass41449DaTarget Relevance information above includes information from UniProt accession: A0A140T913The UniProt Consortium|